Stay updated on INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    A site-wide NIH banner announces a terminology change from “Artificial Intelligence” to “Super Intelligence” under Executive Order 14434, and the footer revision advances from v3.7.1 to v3.7.2. The page continues to display a 403 error.
    Difference
    1%
    Check dated 2026-10-20T21:53:49.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision identifier changed from v3.7.0 to v3.7.1. The page continues to show a 403 Forbidden error rather than the study record.
    Difference
    0.2%
    Check dated 2026-10-06T22:08:39.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The study details page now returns a 403 Forbidden error, replacing the usual content. The Home link and page navigation are no longer available on this page, indicating access is blocked rather than a content update.
    Difference
    0.5%
    Check dated 2026-09-29T22:01:20.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    Access to the study page now shows a 403 Forbidden error, replacing the usual study record content with a minimal error screen that includes a 403 message and a Home button. This indicates restricted access to the page rather than an update to the study details or related content.
    Difference
    18%
    Check dated 2026-09-22T23:06:17.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The page now displays a new revision label, updating from v3.6.6 to v3.7.0. This appears to be a backend or UI version update and does not change any study content or functionality on the page.
    Difference
    0.0%
    Check dated 2026-09-15T20:56:31.000Z thumbnail image
  7. Check
    55 days ago
    Change Detected
    Summary
    The page revision label was updated from v3.6.5 to v3.6.6, indicating a new revision of the page. This reflects maintenance rather than substantive changes to the study information.
    Difference
    0.0%
    Check dated 2026-09-01T19:08:56.000Z thumbnail image

Stay in the know with updates to INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.